Edition:
United Kingdom

Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

534.60INR
6:14am GMT
Change (% chg)

Rs0.10 (+0.02%)
Prev Close
Rs534.50
Open
Rs537.15
Day's High
Rs537.70
Day's Low
Rs532.50
Volume
383,379
Avg. Vol
2,333,173
52-wk High
Rs678.45
52-wk Low
Rs483.75

Chart for

About

Cipla Limited is a holding company. The Company is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered... (more)

Overall

Beta: 0.47
Market Cap(Mil.): Rs471,067.19
Shares Outstanding(Mil.): 804.69
Dividend: 2.00
Yield (%): 0.34

Financials

  CIPL.NS Industry Sector
P/E (TTM): 43.76 29.30 32.54
EPS (TTM): 13.38 -- --
ROI: -- 14.23 13.82
ROE: -- 15.46 15.25

UPDATE 1-India's Cipla Q3 profit falls as lean India sales, tax cost weigh

Feb 6 Cipla Ltd, India's second-largest generic drugmaker by market capitalisation, reported on Wednesday a 17.1 percent drop in quarterly profit, dragged down by higher tax expenses and weak sales in domestic market.

06 Feb 2019

India's Cipla Q3 profit falls, lags estimate

Feb 6 Cipla Ltd, India's second-biggest generic drugmaker by market capitalisation, reported a 17.1 percent fall in third-quarter profit on Wednesday, hurt by higher tax expenses.

06 Feb 2019

UPDATE 1-India's Cipla warns of headwinds in second half after Q2 profit miss

Nov 5 Cipla Ltd, India's second-largest drugmaker by market capitalisation, warned on Monday of "multiple headwinds" in the second half of the financial year after its quarterly profit fell short of analysts' estimates.

05 Nov 2018

India's Cipla Q2 profit dips nearly 11 pct, misses estimate

Nov 5 Drugmaker Cipla Ltd posted a nearly 11 percent fall in second-quarter profit on Monday, much lower than analyst expectations.

05 Nov 2018

Earnings vs. Estimates